Diagnostic imaging agent developer Lantheus Medical Imaging said it has appointed a new chief medical officer.
Dr. Cesare Orlandi brings more than 20 years of pharmaceutical industry experience to the post, Lantheus said. He will be responsible for leading clinical development, pharmacovigilance, and medical and regulatory affairs, including a phase III clinical trial program for flurpiridaz F-18.
Orlandi will report directly to Jeff Bailey, Lantheus' president and CEO, the company said.
